Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"
Change 5-day change 1-year change 3-year change Capi.($)
+5.60%-6.13% - - 303M
+1.44%+1.71%-10.98%-5.59% 43.13B
+3.31%+5.93%+310.97%+532.23% 34.65B
+2.84%+2.14%+9.34%+45.55% 30.03B
-1.70%-7.54%+8.43%-21.54% 28B
-1.90%-1.56%+10.24%+22.81% 24.45B
-0.14%+5.86% - - 14.34B
+0.68%-1.53%+48.76%+108.76% 13.14B
-0.57%-2.43%+5.08%+6.76% 12.53B
-0.26%+1.15%+98.13%+79.60% 12.25B
Average +0.93%+0.73%+60.00%+96.07% 23.61B
Weighted average by Cap. +0.78%+1.27%+65.47%+111.07%
Logo OvaScience Inc
Tempest Therapeutics, Inc.(Tempest), formerly Millendo Therapeutics, Inc., is a clinical-stage oncology company. The Company is focused on developing therapeutics that combine both targeted and immune-mediated mechanisms to treat a wide range of tumors. The Company's two clinical programs are TPST-1495 and TPST-1120. The Company's both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate cGAS/STING pathway, an innate immune response pathway important for the development of anti-tumor immunity.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!